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To the Editor: The prevalence of asthma is increasing
worldwide and the morbidity and mortality attributed to
undiagnosed or inappropriately treated asthma remains
unacceptably high.1 In 2000 the SAMJ1 published a guideline to
help practitioners to diagnose and manage asthma. Even
though guidelines such as this are freely available, many
patients remain less than optimally medicated.2 The present
study recorded the number of previously diagnosed asthmatic
patients presenting at an occupational health clinic and the
extent to which their medication complied with the asthma
guideline.
All asthmatic patients aged 18 years and older who
consulted the chief researcher (SK) during the study period
were included in the study. Patients consulted either because of
an acute exacerbation of asthma or because it was more
convenient for them to obtain a prescription for their
medication from the occupational health facility at the time.
These patients, with medical insurance, had the freedom to
choose their doctor and it is not uncommon for such patients to
consult different doctors for their asthma medication.
All patients agreed to participate in the study. During the
consultation patients were questioned about their medication
(the names and uses thereof) and the severity of their asthma
was assessed as described in the guideline. To avoid bias, those
patients who had been diagnosed with asthma or who were
being treated for asthma by the chief researcher were excluded
from the study.
Over a period of 18 months 33 patients met the inclusion
criteria. The treatment regimen for 21 patients (63.6%)
complied with the asthma guideline. Table I shows that the
treatment regimen for 12 patients (36.4%) did not comply with
the asthma guideline and that the majority of these patients
(66.7%) had moderate to severe asthma. Eleven of the 12
patients (91.7%) did not use a steroid metered-dose inhaler
(patients 2 - 12). Ten of these 11 patients (90.9%) had chronic
persistent asthma and according to the guideline should have
been using an inhaled steroid. One patient with intermittent
asthma was using a cough mixture with bronchodilator
properties and a short-acting β2-stimulant for symptomatic
relief. A patient with moderate asthma was also using a cough
mixture for symptomatic relief. The third patient with
intermittent asthma was correctly using a steroid inhaler but
was using a long-acting instead of a short-acting β2-stimulant
for symptomatic relief.
Discussion
In South Africa the management of asthma is still a problem. In
1996, asthma accounted for 1.4% of deaths in males and 1.6% in
females. The years of life lost showed that asthma accounted
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Denotes medication used*
Table I. Severity of asthma and the treatment regimens of patients who did not comply with the asthma guideline
Patient number 1 2 3 4 5 6 7 8 9 10 11 12
Age (yrs) 31 67 35 58 25 29 43 29 53 53 29 59
Severity of asthma Intermittent Mild Moderate Severe
Inhaled steroid
Inhaled short-acting 
β2-stimulant * * * * * * * * * * *
Short-acting 
β2-stimulant tablets * *
Long-acting
β2-stimulant  * *
Theophylline * * * * *
Atrovent *
Cough mixture with
bronchodilator 
properties
* *
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for 1.1% of male years of life lost and 1.4% of female years of
life lost in the same year.3 This high morbidity and unnecessary
mortality occurred despite readily available and cost-effective
treatment regimens. The aim of clinical guidelines is to
promote good medical practice4 by assisting practitioners to
provide optimal and cost-effective care. Eccles et al.5 in the
former Northern Region of the UK, found that 25% of practices
were not aware of the availability of guidelines for the
management of asthma, diabetes and hypertension.5 Studies
have found that even when clinical guidelines are available
they are not adopted. It is therefore imperative that a strategy
promoting the acceptance and use of clinical guidelines by
practitioners be developed.6 By using asthma guidelines, the
severity of asthma is more likely to be graded accurately and
medicated appropriately. To encourage adherence to the
prescribed regimen it is important for practitioners to ensure
that patients understand the necessity for and the safety of
inhaled steroids. The use of cough mixtures is neither
recommended nor indicated in the management of asthma.
The finding in this study that 36.4% of patients did not
receive the recommended medication commensurate with the
severity of their asthma is cause for concern. If this problem is
not addressed, it is unlikely that there will be an improvement
in the current unacceptably high morbidity and mortality
associated with asthma in South Africa.
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A phosphodiesterase inhibitor promotes the premature
development of adverse cardiac remodelling mediated 
by beta-adrenergic activation in hypertension
To the Editor: Cardiac dilatation is thought to contribute to
pump dysfunction in heart failure. In hypertension, left
ventricular hypertrophy (LVH) can progress from a concentric
geometry to left ventricular (LV) dilatation. The mechanisms
responsible for the transition from concentric LVH to cardiac
dilatation in hypertension are uncertain. In human studies LVH
is associated with an increased sympathetic activity to the
myocardium, but not to other tissue beds.1 Our group has
therefore proposed that sympathetic over-activation in LVH
could mediate the transition from concentric LVH to cardiac
dilatation. Indeed, we have demonstrated that in
spontaneously hypertensive rats (SHRs) with concentric LVH,
daily administration of low doses of a beta-adrenoreceptor 
(β-AR) agonist promotes the development of marked cardiac
dilatation.2 However, β-AR-induced effects can be mediated by
cyclic adenosine monophosphate (cAMP)-dependent and
independent pathways.3 To explore the role of β-AR-cAMP
pathways in mediating the transition from concentric LVH to
LV dilatation, we evaluated the effect of a phosphodiesterase
inhibitor (PDEI), used either alone or with a β-AR agonist, on
LV geometry and function in SHRs with concentric LVH.
Methods
Fourteen-month-old SHRs and Wistar Kyoto (WKY) control
rats were used for this study. SHRs either received no therapy,
a β-AR agonist (isoproterenol, daily as previously described2), a
PDEI (pentoxifylline, 50 mg/kg/day in the drinking water), or
both the β-AR agonist and the PDEI for 3 months. To ensure
that the β-AR agonist was effective, additional SHRs were either
left untreated or received the β-AR agonist for 5.5 months.
LV cavity size was assessed using three techniques. First,
two-dimensional directed M-mode echocardiography was
performed using a Sonos model 2500 Hewlett Packard
echocardiograph with a 7.5 MHz transducer.4 Second, LV end
diastolic (LVED) dimensions were assessed using piezoelectric
ultrasonic transducers placed across the short axis of the heart
at controlled LVED pressures (LVEDP) in open-chest,
ventilated rats.2 Third, LV diastolic pressure-volume relations
were constructed in isolated, perfused heart preparations and
the volume intercept at a diastolic pressure of  0 mmHg 
(LV V0) was determined.
2,4 To assess further the impact of the
β-AR agonist and the PDEI on cardiac remodelling, myocardial
collagen content was determined using hydroxyproline
((HPRO) determinations.2,4
